CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE  Parliamentary submission
DATE  2017-04-06
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act
and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and
Constitutional Affairs

April 6, 2017
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE       Response to consultation
DATE              2016-03-19
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Response:
Consultation on the Prescription Drug List: Naloxone
Health Canada - Prescription Drug Status Committee
March 19, 2016
Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

Policy document

2015-05-30

Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
  Population health, health equity, public health

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policyl3927

POLICY TYPE: Response to consultation
DATE: 2018-08-14
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE  Parliamentary submission
DATE  2013-11-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/link/policy13932

POLICY TYPE  Policy endorsement
DATE  2018-10-31
TOPICS  Population health, health equity, public health

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE  Response to consultation
DATE  2014-07-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE  Response to consultation
DATE  2014-03-17
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE  Parliamentary submission
DATE  2016-10-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Population health, health equity, public health
        Health care and patient safety

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents